Efficacy and Side-Effect Profile of Foslevodopa-Foscarbidopa Subcutaneous Infusion in Patients with Advanced Parkinson's Disease: An Ambispective Longitudinal Study.
Efficacy and Side-Effect Profile of Foslevodopa-Foscarbidopa Subcutaneous Infusion in Patients with Advanced Parkinson's Disease: An Ambispective Longitudinal Study.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Delhi, IN · Author affiliation
Neurology, https://ror.org/02dwcqs71All India Institute of Medical Sciences, Delhi, India.Location evidence
CA · Author affiliation · country only
Neurological Sciences, University of Western Ontario Schulich School of Medicine & Dentistry, Canada.Location evidence
London, CA · Author affiliation
CNS, University of Western Ontario, London Health Sciences Centre, Canada.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
BackgroundFoslevodopa-foscarbidopa (LDp/CDp) is a soluble formulation of levodopa/carbidopa delivered as a continuous subcutaneous infusion for the treatment of motor fluctuations in people with Parkinson's disease. No real-world use data exist regarding its efficacy and safety from a high-volume Canadian center.MethodsThis is an ambispective longitudinal study (with the second visit at 1 month of enrollment) in patients with advanced Parkinson's disease from a tertiary care movement disorder center in Canada.ObjectivesThe primary objective of the study was to examine the efficacy of LDp/CDp in improving MDS UPDRS III scores, EURO-Q Index, EURO Q VAS score and ON time while reducing OFF time. Secondary objectives focused on safety.ResultsThe study was conducted from April 2024 to August 2025, with the prospective part comprising 11 patients and the retrospective part 53 patients. There was a significant (p < 0.05) improvement in clinical efficacy parameters like the MDS UPDRS III (-11.37), OFF hours (-2.77), ON time without dyskinesias (+2.07), ON time with troublesome dyskinesias (-0.74 hours) and quality of life-related parameters like EURO Q Index (+0.10) and PDQ-39 (-10.78). One-fourth (26.5%) of the patients discontinued treatment, mostly due to infusion-site reactions or infections.ConclusionLDp/CDp can be an effective treatment option for carefully selected patients with advanced Parkinson's disease and disabling motor complications. Appropriate hygiene measures may reduce the proportion of infusion site reactions, thereby improving patient retention on LDp/CDp infusion.